Depression-dispelling nerve-soothing granules and preparation method for oral solution of same
A technology of Jieyu Anshen Granules and Fushen, which is applied in the preparation of Jieyu Anshen Granules and its oral liquid, and in the field of pure traditional Chinese medicine compositions for insomnia and neurasthenia, which can solve the problems of low toxic and side effects and inability to cure severe patients, and achieve side effects Small size, significant curative effect, safe and reliable effect
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2013-11-06
Abstract
Description
Technical field
[0001] The invention relates to a Jieyu Anshen granule and a preparation method for its oral liquid, in particular to a pure Chinese medicine composition suitable for insomnia and neurasthenia, and belongs to the technical field of Chinese medicine. Background technique
[0002] Sleep is one of the important objective indicators of human health and is closely related to human health. As the pace of modern life accelerates, more and more people suffer from insomnia, which is seriously disturbing people's life, work, study and their physical health. Insomnia is mainly manifested in insufficient sleep time, depth, and inability to eliminate fatigue and restore physical strength and energy. The disease can also induce anxiety, decreased memory, decreased immunity, palpitations, chest numbness, dizziness, headache, stroke and other symptoms. Although many drugs are currently used for the treatment of insomnia, none of them can achieve the purpose of radical cure. Wes...
Examples
Embodiment Construction
[0038] The present invention is further illustrated through clinical observations and examples. However, the scope of the present invention is not limited to the following examples.
[0039] 1. Example 1 and clinical observation data
[0040] 1. General clinical data: In order to verify the actual efficacy of the drug of the present invention, 100 patients were treated with the drug of the present invention in combination with clinical treatment of insomnia. The age distribution is as follows: 18 cases under 30 years old, 20 cases 30-40 years old, 40-50 years old 38 cases were aged 50-60 years, 18 cases were 50-60 years old, 16 cases were over 60 years old; the oldest was 78 years old, and the youngest was 19 years old.
[0041] 2. Diagnostic indicators
[0042] Clinical symptoms:
[0043] (1) Light people have difficulty sleeping or awakening easily after sleep, insomnia after waking up, and severe people can't sleep at night.
[0044] (2) Often accompanied by headaches, dizziness, pal...